We are pleased to welcome Mike Exton, Ph.D. as our new chief executive officer! #Lexicon
Lexicon Pharmaceuticals, Inc.
Pharmaceutical Manufacturing
The Woodlands, TX 19,541 followers
At Lexicon, We Pioneer Medicines that Transform Patients' Lives
About us
Corporate Overview Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. The Genome: Our Source of Discovery We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. A Diverse Pipeline of Targeted Therapies Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.
- Website
-
http://www.lexpharma.com/
External link for Lexicon Pharmaceuticals, Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- The Woodlands, TX
- Type
- Public Company
- Founded
- 1995
- Specialties
- biopharma, knockout, novel drug, innovation, disease, and pharmaceutical
Locations
-
Primary
Get directions
8800 Technology Forest
The Woodlands, TX 77381, US
-
Get directions
-
Get directions
110 Allen Rd
Basking Ridge, NJ 07920, US
Employees at Lexicon Pharmaceuticals, Inc.
Updates
-
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director. To view the full press release, visit our website: bit.ly/4cupezv #LexiconNews
-
-
We’re headed to Nashville for the 2024 American Association of Nurse Practitioners (AANP) meeting. Stop by Booth #1248 to learn more about an FDA-approved product for heart failure. #HeartFailure #AANP24
-
We’re in Orlando for the 84th annual ADA Scientific Sessions! Join us tomorrow at 12:30 PM ET in the Poster Hall for a presentation on a sub-study of RELIEF-DPN 1. Learn more about our participation at #ADASciSessions: bit.ly/3KKuAKS #LexiconNews #DPNP
-
-
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes. To view the full press release, visit our website: bit.ly/4bdnVUj #LexiconNews #T1D #Type1Diabetes
-
-
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association. To view the full press release, visit our website: bit.ly/3xfgiyT #LexiconNews #ADASciSessions #DiabetesCare #DPNP
-
-
We’re attending the 20th annual American Association of Heart Failure Nurses (AAHFN) meeting in Orlando. Visit Booth #213 to connect with us about an FDA-approved product for heart failure. #HeartFailure #AAHFN2024
-
Analysis of INPEFA® (sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology. To view the full press release, visit our website: bit.ly/3VNp68o #LexiconNews
-
-
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association. To view the full press release, visit our website: bit.ly/3KKuAKS #LexiconNews #ADASciSessions
-
-
We’re at the 8th annual Heart in Diabetes (HiD) conference in Philadelphia! Join us at the Breakfast Session on Saturday morning to hear more from Drs. Javed Butler and Salim Hayek on “Harnessing SGLT Inhibition in the Treatment and prevention of HF.” #HiD24
Affiliated pages
Similar pages
Browse jobs
Stock
LXRX
NASDAQ
20 minutes delay
$1.59
-0.015 (-0.938%)
- Open
- 1.6
- Low
- 1.56
- High
- 1.6
Data from Refinitiv
See more info on